The Mumbai-based Glenmark Pharmaceuticals Ltd is planning to expand its product portfolio in Brazil with 22 products in pipeline to be launched by next year, as the market is reporting higher growth along with a potential to serve the Latin American market as a whole.
Glenmark Pharma, one of the select Indian companies having wholly owned subsidiary Glenmark Farmaceutica Ltda (GFL) in Brazil, is currently marketing 28 of its products in therapeutic areas like derma, respiratory, gynaecology, endocrinology and oncology. The company will explore the potential of the region for strategic development in future, informed the company spokesperson.
The details can be read here.
No comments:
Post a Comment